2019年第46卷第7期目录
|
|
封面故事:鳞癌细胞抗原(SCC)和细胞角蛋白19片段(CYFRA21-1)是目前临床上广泛使用的肺鳞状细胞癌特异性血清标志物. 然而SCC肿瘤检测敏感性低,CYFRA21-1严重依赖肿瘤阶段,对肺鳞癌晚期具有较高的敏感性,两者均不利于肺鳞癌的早期诊断. DNA甲基化异常是肿瘤早期的频发事件,此外,DNA甲基化随着时间的推移相对稳定并且可以在血液中非侵入性地检测到,因此DNA甲基化具有成为癌症早期诊断生物标志物的巨大潜力. 王学栋等通过对多种癌症早期甲基化数据进行比较,筛选得到六个肺鳞癌早期特异性的诊断标志位点,对于早期肺鳞癌检测具有极高的敏感性,为肺鳞癌的早期诊断提供了潜在的生物标志物,也为其余癌型特异性诊断标志物的筛选提供新的思路.
(王学栋,尚文慧,李晓琴,常宇. 肺鳞状细胞癌特异性甲基化候选诊断标志物的识别,本期第680~688页)
Cover Story:DNA methylation abnormalities are frequent events in early tumors. Additionally, DNA methylation is relatively stable over time and can be non-invasively detected in blood. Therefore, DNA methylation has a great potential to become an early diagnostic biomarker of cancers. In order to find potential diagnostic markers for lung squamous cell carcinoma (LUSC), a method for identifying LUSC-specific candidate diagnostic markers was proposed. We screened 6 LUSC-specific CpGs by comparing the methylation profiles of 172 samples from LUSC patients, 42 normal lung samples, 184 normal blood samples, and 1 306 samples from patients with other cancers which was collected from TCGA (The Cancer GenomeAtlas) database. A supportvector machine model was constructed to distinguish LUSC patients from normal controls. The combination of six sites achieved 93%-99% sensitivity in predicting LUSC, 100% specificity in excluding all normal samples, and ~?99% specificity in excluding other cancers. Overall, our study provides promising biomarkers for the diagnosis of LUSC.
|
综述与专论
研究报告
技术与方法
新技术讲座
|
|